Activating mutations in these genes may not only promote the development of melanoma but also reduce the effectiveness of BRAF/MEK inhibitors as a result of activation of the MAPK pathway despite the inhibition of BRAF kinase [59]. Here, MAP2K7 is linked to melanoma.